Women with recurrent pregnancy loss or advanced maternal age who carry thyroid antibodies can take some reassurance from a new study: their embryos appear no more likely to be chromosomally abnormal than those of women with healthy thyroid glands.
The study focused on two groups of patients undergoing in vitro fertilization who face elevated reproductive risks: women with recurrent pregnancy loss, defined as repeated miscarriages, and women of advanced maternal age. Both groups underwent preimplantation genetic testing for aneuploidy, or PGT-A, a laboratory technique that screens embryos for missing or extra chromosomes before they are transferred to the uterus.
Researchers divided the participants into comparison groups based on thyroid status. One set of comparisons separated women with thyroid autoimmunity, in which the immune system produces antibodies that attack the thyroid gland, from women without such antibodies. A second set separated women with overt hypothyroidism from women whose thyroid function was normal. The investigators then measured euploidy rates—the proportion of blastocysts, or day-five to day-seven embryos, that tested chromosomally normal—and tracked the outcomes of transfers that used only euploid embryos.
The results on embryo quality were strikingly consistent. Blastocyst euploidy rates did not differ significantly between the thyroid autoimmunity group and the non-autoimmune group. The same held true for overt hypothyroidism: euploidy rates in that group were statistically indistinguishable from those in women with normal thyroid function. In other words, neither the presence of thyroid antibodies nor a severely underactive thyroid appeared to make embryos more likely to carry chromosomal errors, at least in this population of women already undergoing genetic screening of their embryos.
Transfer outcomes told a similar story for autoimmunity. When only chromosomally normal embryos were transferred, women with thyroid autoimmunity achieved clinical pregnancy and live birth rates comparable to those of women without it, with no statistically significant differences in any measured outcome. The study’s conclusion was direct: thyroid autoimmunity might not have adverse effects on euploid embryo transfer outcomes among women with recurrent pregnancy loss and advanced maternal age.
Overt hypothyroidism presented a more nuanced picture. Among women with recurrent pregnancy loss, the clinical pregnancy rate and live birth rate per euploid embryo transfer were both lower in the hypothyroid group than in the normal thyroid function group, and the miscarriage rate was higher. The study’s authors characterized overt hypothyroidism as potentially having slightly adverse effects on euploid embryo transfer outcomes in patients with recurrent pregnancy loss, a cautious formulation that acknowledges the direction of the observed differences without overstating their certainty.
Where overt hypothyroidism did show statistically significant effects was in pregnancy-related complications and newborn characteristics. Among women with recurrent pregnancy loss, the incidence of pregnancy-related complications was significantly greater in the overt hypothyroidism group than in the normal thyroid function group. Among women of advanced maternal age, the body weights of newborns were significantly lower in the overt hypothyroidism group.
The study’s design deserves attention when interpreting these results. Because all participants underwent PGT-A, the researchers could separate the question of embryo chromosome status from the question of whether a pregnancy, once established with a normal embryo, progresses successfully.
Thyroid autoimmunity, in the absence of overt thyroid dysfunction, does not appear to compromise embryo chromosomal normality or the success of euploid embryo transfer in this population. Overt hypothyroidism, meanwhile, did not appear to increase aneuploidy risk but was associated with significantly higher rates of pregnancy complications among women with recurrent pregnancy loss and significantly lower newborn birth weights among women of advanced maternal age.
Subject of Research: Effects of overt hypothyroidism and thyroid autoimmunity on embryo aneuploidy risk and pregnancy outcomes after euploid embryo transfer in women with recurrent pregnancy loss and advanced maternal age
Article Title: Effects of overt hypothyroidism and thyroid autoimmunity on the risk of embryo aneuploidy and pregnancy outcomes resulting from euploid embryo transfer
Article References: Leng, M., Zhang, L., Liu, C., Wang, J., Jin, J., Luan, Y., Zhang, J., & Guan, Y. (2026). Effects of overt hypothyroidism and thyroid autoimmunity on the risk of embryo aneuploidy and pregnancy outcomes resulting from euploid embryo transfer. BMC Pregnancy and Childbirth. https://doi.org/10.1186/s12884-026-10129-w
Image Credits: AI Generated
DOI: 10.1186/s12884-026-10129-w
Keywords: thyroid autoimmunity, overt hypothyroidism, embryo aneuploidy, euploid embryo transfer, recurrent pregnancy loss, advanced maternal age, PGT-A, IVF, blastocyst euploidy, pregnancy complications, live birth rate, miscarriage
News Source: Ophelia Keating. (November 7, 2026). Thyroid Autoimmunity Does Not Raise Embryo Aneuploidy Risk in IVF Patients. Scienmag.



